# Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo

> **NCT02192554** · — · COMPLETED · sponsor: **Otsuka Pharmaceutical Development & Commercialization, Inc.** · enrollment: 450 (actual)

## Conditions studied

- Agitation Associated With Alzheimer's Disease
- Alzheimer's Type
- Mental Disorder
- Nervous System Diseases

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02192554
- **Lead sponsor:** Otsuka Pharmaceutical Development & Commercialization, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06
- **Primary completion:** 2017-05
- **Final completion:** 2017-05
- **Target enrollment:** 450 (ACTUAL)
- **Last updated:** 2018-04-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02192554

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02192554, "Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02192554. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*